BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Nanoscope Therapeutics & Nippon Shinyaku to commercialise MCO-010 in Japan for treatment of inherited retinal dystrophies

November 24, 2026 | News

Inherited retinal dystrophies continue to represent a significant unmet medical need in Japan



US-based Nanoscope Therapeutics, Inc. and Japan's Nippon Shinyaku have entered into an exclusive commercialisation agreement in Japan for MCO-010 (MOGENRY®), a potential treatment for inherited retinal dystrophies (IRDs).

IRDs are a group of rare diseases characterized by progressive impairment of visual function due to degeneration of retinal photoreceptor cells caused by a wide range of genetic mutations. IRDs include retinitis pigmentosa (RP), Stargardt disease, cone-rod dystrophy, and Leber congenital amaurosis, among others. A large number of genes are known to cause IRDs, and treatment options remain limited for many patients.

RP is one of the most common forms of IRDs and is designated as an intractable disease in Japan. In RP, progressive degeneration of retinal photoreceptor cells leads to deterioration of visual function, with symptoms including night blindness and decline of visual acuity. As the disease progresses, patients may develop severe visual impairment.

MCO-010 is an optogenetics therapy administered as a single intravitreal injection and utilizes Nanoscope’s proprietary MCO (Multi-Characteristic Opsin) technology.

In September 2026, Nanoscope filed a marketing authorisation application in Japan for MCO-010, with inherited retinal dystrophies with severe vision loss as the proposed indication. If approved, MOGENRY has the potential to become a new treatment option for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing.